MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 15, 2005; DOI: 10.1124/mol.105.012435


0026-895X/05/6801-49-60$20.00
Mol Pharmacol 68:49-60, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.012435v1
68/1/49    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balzarini, J.
Right arrow Articles by Gago, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balzarini, J.
Right arrow Articles by Gago, F.

The Amino Acid Asn136 in HIV-1 Reverse Transcriptase (RT) Maintains Efficient Association of Both RT Subunits and Enables the Rational Design of Novel RT Inhibitors

Jan Balzarini, Joeri Auwerx, Fátima Rodríguez-Barrios, Allel Chedad, Viktor Farkas, Francesca Ceccherini-Silberstein, Carlos García-Aparicio, Sonsoles Velázquez, Erik De Clercq, Carlo-Federico Perno, María-José Camarasa, and Federico Gago

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium (J.B., J.A., E.D.C.); Department of Pharmacology, University of Alcalá, Alcalá de Henares, Spain (F.R.-B., F.G.); Faculty of Sciences, Katholieke Universiteit Leuven, Kortrijk Campus, Kortrijk, Belgium (A.C.); Department of Organic Chemistry, Eötvös Loránd University, Budapest, Hungary (V.F.); Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy (F.C.-S., C.-F.P.); and Instituto de Química Médica, Consejo Superior de Investigaciones Cientificas, Madrid, Spain (C.G.-A., S.V., M.-J.C.)

The highly conserved Asn136 is in close proximity to the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI)-specific lipophilic pocket of human immunodeficiency virus type 1 (HIV-1) RT. Site-directed mutagenesis has revealed that the catalytic activity of HIV-1 RT mutated at position Asn136 is heavily compromised. Only 0.07 to 2.1% of wild-type activity is retained, depending on the nature of the amino acid change at position 136. The detrimental effect of the mutations at position 136 occurred when the mutated amino acid was present in the p51 subunit but not in the p66 subunit of the p51/p66 RT heterodimer. All mutant enzymes could be inhibited by second-generation NNRTIs such as efavirenz. They were also markedly more sensitive to the inactivating (denaturating) effect of urea than wild-type RT, and the degree of increased urea sensitivity was highly correlated with the degree of (lower) catalytic activity of the mutant enzymes. Replacing wild-type Asn136 in HIV-1 RT with other amino acids resulted in notably increased amounts of free p51 and p66 monomers. Our findings identify a structural/functional role for Asn136 in stabilization of the RT p66/p51 dimer and provide hints for the rational design of novel NNRTIs or drugs targeting either Asn136 in the {beta}7–{beta}8 loop of p51 or its anchoring point on p66 (the peptide backbone of His96) so as to interfere with the RT dimerization process and/or with the structural support that the p51 subunit provides to the p66 subunit and which is essential for the catalytic enzyme activity.


Received March 1, 2005; accepted April 12, 2005

Address correspondence to: Prof. J. Balzarini, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail: jan.balzarini{at}rega.kuleuven.be




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
J. Auwerx, F. Rodriguez-Barrios, F. Ceccherini-Silberstein, A. San-Felix, S. Velazquez, E. De Clercq, M.-J. Camarasa, C.-F. Perno, F. Gago, and J. Balzarini
The Role of Thr139 in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Sensitivity to (+)-Calanolide A
Mol. Pharmacol., September 1, 2005; 68(3): 652 - 659.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics